Cg Oncology Common Stock Price Patterns
| CGON Stock | 51.50 0.12 0.23% |
Momentum 60
Buy Extended
Oversold | Overbought |
EPS Estimate Next Quarter (0.56) | EPS Estimate Current Year (2.08) | EPS Estimate Next Year (2.58) | Wall Street Target Price 79.8571 | EPS Estimate Current Quarter (0.55) |
Using CG Oncology hype-based prediction, you can estimate the value of CG Oncology Common from the perspective of CG Oncology response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards CG Oncology using CG Oncology's stock options and short interest. It helps to benchmark the overall future attitude of investors towards CGON using crowd psychology based on the activity and movement of CG Oncology's stock price.
CG Oncology Short Interest
An investor who is long CG Oncology may also wish to track short interest. As short interest increases, investors should be becoming more worried about CG Oncology and may potentially protect profits, hedge CG Oncology with its derivative instruments, or be ready for some potential downside.
200 Day MA 35.6652 | Short Percent 0.1179 | Short Ratio 6.37 | Shares Short Prior Month 9.4 M | 50 Day MA 47.0398 |
CG Oncology Common Hype to Price Pattern
Investor biases related to CG Oncology's public news can be used to forecast risks associated with an investment in CGON. The trend in average sentiment can be used to explain how an investor holding CGON can time the market purely based on public headlines and social activities around CG Oncology Common. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Some investors profit by finding stocks that are overvalued or undervalued based on market sentiment. The correlation of CG Oncology's market sentiment to its price can help taders to make decisions based on the overall investors consensus about CG Oncology.
CG Oncology Implied Volatility | 1.4 |
CG Oncology's implied volatility exposes the market's sentiment of CG Oncology Common stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if CG Oncology's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that CG Oncology stock will not fluctuate a lot when CG Oncology's options are near their expiration.
The fear of missing out, i.e., FOMO, can cause potential investors in CG Oncology to buy its stock at a price that has no basis in reality. In that case, they are not buying CGON because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
CG Oncology after-hype prediction price | USD 51.73 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Prediction based on Rule 16 of the current CGON contract
Based on the Rule 16, the options market is currently suggesting that CG Oncology Common will have an average daily up or down price movement of about 0.0875% per day over the life of the 2026-04-17 option contract. With CG Oncology trading at USD 51.5, that is roughly USD 0.0451 . If you think that the market is fully incorporating CG Oncology's daily price movement you should consider acquiring CG Oncology Common options at the current volatility level of 1.4%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Check out CG Oncology Basic Forecasting Models to cross-verify your projections. CG Oncology After-Hype Price Density Analysis
As far as predicting the price of CG Oncology at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in CG Oncology or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of CG Oncology, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
CG Oncology Estimiated After-Hype Price Volatility
In the context of predicting CG Oncology's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on CG Oncology's historical news coverage. CG Oncology's after-hype downside and upside margins for the prediction period are 47.04 and 56.42, respectively. We have considered CG Oncology's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models compare with traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
CG Oncology is very steady at this time. Analysis and calculation of next after-hype price of CG Oncology Common is based on 3 months time horizon.
CG Oncology Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as CG Oncology is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading CG Oncology backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with CG Oncology, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.46 | 4.69 | 0.23 | 0.13 | 8 Events / Month | 8 Events / Month | In about 8 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
51.50 | 51.73 | 0.45 |
|
CG Oncology Hype Timeline
CG Oncology Common is currently traded for 51.50. The entity has historical hype elasticity of 0.23, and average elasticity to hype of competition of 0.13. CGON is estimated to increase in value after the next headline, with the price projected to jump to 51.73 or above. The average volatility of media hype impact on the company the price is over 100%. The price boost on the next news is projected to be 0.45%, whereas the daily expected return is currently at 0.46%. The volatility of related hype on CG Oncology is about 1639.86%, with the expected price after the next announcement by competition of 51.63. The company reported the previous year's revenue of 1.14 M. Net Loss for the year was (88.04 M) with loss before overhead, payroll, taxes, and interest of (112.89 M). Given the investment horizon of 90 days the next estimated press release will be in about 8 days. Check out CG Oncology Basic Forecasting Models to cross-verify your projections.CG Oncology Related Hype Analysis
Having access to credible news sources related to CG Oncology's direct competition is more important than ever and may enhance your ability to predict CG Oncology's future price movements. Getting to know how CG Oncology's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how CG Oncology may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| CELC | Celcuity LLC | (0.71) | 9 per month | 2.07 | 0.15 | 5.87 | (3.08) | 17.89 | |
| AAPG | Ascentage Pharma Group | (0.41) | 8 per month | 0.00 | (0.14) | 5.25 | (6.36) | 16.72 | |
| CNTA | Centessa Pharmaceuticals PLC | (0.25) | 9 per month | 2.33 | 0.04 | 4.97 | (3.05) | 26.54 | |
| APGE | Apogee Therapeutics Common | (0.58) | 7 per month | 2.86 | 0.08 | 5.32 | (4.24) | 23.21 | |
| XENE | Xenon Pharmaceuticals | (0.32) | 8 per month | 1.83 | 0.03 | 3.78 | (2.67) | 10.56 | |
| TVTX | Travere Therapeutics | 1.82 | 9 per month | 0.00 | (0.08) | 5.65 | (6.98) | 28.55 | |
| RARE | Ultragenyx | (0.78) | 8 per month | 0.00 | (0.07) | 7.73 | (4.30) | 51.23 | |
| LEGN | Legend Biotech Corp | (0.06) | 9 per month | 0.00 | (0.27) | 3.97 | (6.84) | 19.65 | |
| IRON | Disc Medicine | 4.26 | 5 per month | 0.00 | (0.15) | 4.33 | (7.75) | 14.87 | |
| TARS | Tarsus Pharmaceuticals | (0.11) | 8 per month | 0.00 | (0.14) | 3.78 | (3.91) | 10.88 |
CG Oncology Additional Predictive Modules
Most predictive techniques to examine CGON price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for CGON using various technical indicators. When you analyze CGON charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About CG Oncology Predictive Indicators
The successful prediction of CG Oncology stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as CG Oncology Common, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of CG Oncology based on analysis of CG Oncology hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to CG Oncology's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to CG Oncology's related companies. | 2023 | 2024 | 2025 | 2026 (projected) | Days Sales Outstanding | 164.61 | 250.28 | 225.25 | 198.8 | PTB Ratio | 13.4 | 2.44 | 2.81 | 2.67 |
Pair Trading with CG Oncology
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CG Oncology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CG Oncology will appreciate offsetting losses from the drop in the long position's value.Moving together with CGON Stock
Moving against CGON Stock
| 0.58 | OSE | OSE Pharma SA | PairCorr |
| 0.42 | RAC | Race Oncology Earnings Call Next Week | PairCorr |
| 0.42 | CDIOW | Cardio Diagnostics | PairCorr |
| 0.41 | DRMA | Dermata Therapeutics | PairCorr |
| 0.37 | ALSEN | Sensorion SA | PairCorr |
| 0.33 | VCYT | Veracyte | PairCorr |
The ability to find closely correlated positions to CG Oncology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CG Oncology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CG Oncology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CG Oncology Common to buy it.
The correlation of CG Oncology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CG Oncology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CG Oncology Common moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CG Oncology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out CG Oncology Basic Forecasting Models to cross-verify your projections. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Will Biotechnology sector continue expanding? Could CGON diversify its offerings? Factors like these will boost the valuation of CG Oncology. Projected growth potential of CGON fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every CG Oncology data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (2.05) | Revenue Per Share | Quarterly Revenue Growth 37.744 | Return On Assets | Return On Equity |
Investors evaluate CG Oncology Common using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating CG Oncology's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause CG Oncology's market price to deviate significantly from intrinsic value.
It's important to distinguish between CG Oncology's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding CG Oncology should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, CG Oncology's market price signifies the transaction level at which participants voluntarily complete trades.